Design, synthesis, and SAR of macrocyclic tertiary carbinamine BACE-1 inhibitors.
Lindsley, S.R., Moore, K.P., Rajapakse, H.A., Selnick, H.G., Young, M.B., Zhu, H., Munshi, S., Kuo, L., McGaughey, G.B., Colussi, D., Crouthamel, M.C., Lai, M.T., Pietrak, B., Price, E.A., Sankaranarayanan, S., Simon, A.J., Seabrook, G.R., Hazuda, D.J., Pudvah, N.T., Hochman, J.H., Graham, S.L., Vacca, J.P., Nantermet, P.G.(2007) Bioorg Med Chem Lett 17: 4057-4061
- PubMed: 17482814 
- DOI: https://doi.org/10.1016/j.bmcl.2007.04.072
- Primary Citation of Related Structures:  
2PH6 - PubMed Abstract: 
This Letter describes the design and synthesis of tertiary carbinamine macrocyclic inhibitors of the beta-secretase (BACE-1) enzyme. These macrocyclic inhibitors, some of which incorporate novel P2 substituents, display a 2- to 100-fold increase in potency relative to the previously described acyclic analogs while affording greater stability.
Organizational Affiliation: 
Department of Medicinal Chemistry, Merck Research Laboratories, PO Box 4, West Point, PA 19486, USA.